74 results about "Cowpox virus" patented technology

A rabbit hide containing novel bioactive material for preparing medicine and health-care product is produced through inoculating the cowpox virus in the body of rabbit, raising it until the cowpox is better developed in skin tissue, and killing the rabbit.

This invention relates to methods and systems for generating a safe and effective oral smallpox vaccine for humans using a genetically defective strain of vaccinia virus to confer immunity following oral delivery of the vaccine. This invention is one that expands on current use of vaccinia virus propagation developed for gene therapy applications, and pharmaceuticals and nutraceuticals packaging and formualtion technologies. The vaccine invention can be delivered as a live virus with the ability to express viral proteins but unable to achieve complete, lytic virus replication, or it may be derived from such a virus, contain additional immunogens, or be delivered as viral antigens. Furthermore, the invention establishes innovative methods for formulation and packaging and for preclinical testing of the vaccine invention for safety, efficacy and potency with the use of human intestinal and other test cells and diagnostic test systems and kits.

Described are diagnostic and pharmaceutical compositions comprising a microorganism or cell containing a DNA sequence encoding a detectable protein or a protein capable of inducing a detectable signal, e.g. a luminescent or fluorescent protein, and, in a particular embodiment, furthermore (a) DNA sequence(s) encoding (a) protein(s) suitable for tumor therapy and / or elimination of metastatic tumors, e.g. a cytotoxic or cytostatic protein.

The present invention relates to the identification of gene sequences and proteins involved in vaccinia virus dominant T cell epitopes. Two vaccinia virus CD8+ T cell epitopes restricted by the most common human MHC class I allele, HLA-A0201 have been identified. Both epitopes are highly conserved in vaccinia and variola viruses. The induction of the T cell responses following primary vaccination is demonstrated by the kinetics of epitope specific CD8+ T cells in 3 HLA-A0201 individuals. This information will be useful for the design and analyses of the immunogenicity of experimental vaccinia vaccines, and for basic studies of human T cell memory.

The present invention relates to recombinant modified vaccinia Ankara (MVA) virus containing restructured sites useful for the integration of heterologous nucleic acid sequences into an intergenic region (IGR) of the virus genome, where the IGR is located between two adjacent, essential open reading frames (ORFs) of the vaccinia virus genome, wherein the adjacent essential ORFs are non-adjacent in a parental MVA virus used to construct the recombinant MVA virus, and to related nucleic acid constructs useful for inserting heterologous DNA into the genome of a vaccinia virus, and further to the use of the disclosed viruses as a medicine or vaccine.

The invention discloses porcine reproductive and respiratory syndrome virus M protein CTL cell epitopes and application thereof. The identification of the epitopes comprises the following steps of: fusing and cloning a M protein gene of a porcine reproductive and respiratory syndrome virus CH-1a strain and a mouse ubiquitin gene to form a DNA vaccine and also form recombination viruses, expressing an M protein, of a WR strain vaccinia virus; immunizing a BALB / c mouse according to a Priming-Boosting policy, separating the mouse splenic lymphocyte, culturing and stimulating a CTL short peptide in vitro predicted and synthesized by a bioinformatic method, and using the flow cytometry and enzyme-linked immunospot technology to identify two CTL epitopes that are K93FITSRCRL and F57GYMTFVHF. The identification of the PRRSVM protein CTL cell epitopes lays a certain theoretical foundation for the PRRS cell immune mechanism and the novel epitope pepetide vaccine and has an instructing significance for the theoretical study on PRRS preventing and control technology.

[Problem]To provide a set of virus vectors which can be used for producing a prime / boost vaccine that can activate both cellular immunity and humoral immunity and is effective on infections by pathogenic microorganisms and malignant tumors which are generally believed to be difficult to be treated by vaccine therapy.[Solution]Provided is a set of virus vectors for prime / boost vaccines, comprising the following virus vector (a) and virus vector (b): (a) a vaccinia virus vector which carries a gene encoding an immunogenic polypeptide in such a manner that the gene can be expressed; and (b) a Sendal virus vector which carries the gene encoding the immunogenic polypeptide in such a manner that the gene can be expressed.

The invention provides attenuated vaccinia virus vaccines that can be used in methods to prevent or treat small pox in patients, as well as methods of obtaining such vaccines.

The invention discloses a porcine reproductive and respiratory syndrome-Ankara vaccinia virus genetic engineering vaccine, the preparation method is that: 1. the PCR amplification of GP5 gene is carried out from the natural porcine reproductive and respiratory syndrome virus; 2. the porcine preferred codon is used for replacing the codon in the natural GP5 gene, so as to carry out GP5 gene optimization and the synthesis of the optimized sequence GP5A; 3. the epitope A in the optimized GP5A gene is replaced by the epitope B of the GP5 gene, so as to obtain the GP5-DB gene; 4. the GP5 and GP5-DB genes are respectively cloned to the expression carrier JN-2; 5. the constructed JN-2-GP5 and the JN-2-GP5-DB plasmid are recombined with Ankara vaccinia virus, so as to obtain the porcine reproductive and respiratory syndrome GP5 and GP5-DB gene Ankara vaccinia virus recombinant vaccine. Experiments confirm that the invention has excellent immune protection in BALB / c mice and pigs.

The present invention relates to recombinant modified vaccinia Ankara (MVA) virus containing restructured sites useful for the integration of heterologous nucleic acid sequences into an intergenic region (IGR) of the virus genome, where the IGR is located between two adjacent, essential open reading frames (ORFs) of the vaccinia virus genome, wherein the adjacent essential ORFs are non-adjacent in a parental MVA virus used to construct the recombinant MVA virus, and to related nucleic acid constructs useful for inserting heterologous DNA into the genome of a vaccinia virus, and further to the use of the disclosed viruses as a medicine or vaccine.

The present invention relates to methods for purification of Vaccinia viruses (VV) and / or Vaccinia virus (VV) particles, which can lead to highly pure and stable virus preparations of predominantly biologically active viruses. The invention encompasses purifying a virus preparation in a sterilized way with high efficiency and desirable yield in terms of purity, biological activity and stability, aspects advantageous for industrial production.

Methods of enhancing cellular responses to interferons are disclosed. These methods comprise administering to a subject a vector comprising a Stat1-CC transgene, such as an AAV5 vector comprising a reporter operably linked to a nucleic acid sequence encoding a Stat1-CC polypeptide. The methods can be used in the treatment of diseases that involve interferon responses, such as multiple sclerosis, amyotrophic lateral sclerosis, and lupus; viral infections such as infection by hepatitis C virus, influenza A virus, cowpox virus, Sendai virus or Encephalomyocarditis virus; respiratory disorders; and cancers.

The technology of the present disclosure relates to the use of Heat-inactivated modified vaccinia Ankara (MVA) virus (Heat-iMVA) or Heat-inactivated vaccinia virus as a vaccine immune adjuvant. In particular, the present technology relates to the use of Heat-iMVA as a vaccine adjuvant for tumor antigens in cancer vaccines alone or in combination with immune checkpoint blockade (ICB) antibodies foruse as a cancer immunotherapeutic.

The invention relates to a nucleic acid combination product, a detection kit and a micro-fluidic chip. The nucleic acid combination product comprises at least two of the following detection primer pairs: a feline parvovirus primer pair, a feline coronavirus primer pair, a feline herpesvirus type I primer pair, a feline calicivirus primer pair, a feline leukemia virus primer pair, a feline immunodeficiency virus primer pair, a feline astrovirus primer pair, a feline rotavirus primer pair, a cat vaccinia virus primer pair and a cat reovirus primer pair. The nucleic acid combination product can be used for detecting at least two feline pathogenic viruses in the sample to be detected at one time, and is good in specificity and relatively high in detection sensitivity.

The present invention discloses recombinant vaccinia virus (VV) virions that are resistant to antiviral defenses and have enhanced anti-tumor activities. In one embodiment, the recombinant VV comprise one or more variant VV proteins that have mutations at one or more neutralizing antibody epitopes, thereby conferring viral escape from the neutralizing antibodies. In another embodiment, the recombinant VV is resistant to complement-mediated neutralization due to the expression of a regulator of complement activation (e.g. CD55). In another embodiment, the recombinant VV has enhanced anti-tumor activities due to the expression of bi-specific antibodies co-targeting cancer cells and immune effector cells, or the expression of a polypeptide blocking the PD-1 pathway. The recombinant vaccinia virus virions can be used to treat cancer in a subject.

The present invention provides compositions and methods for generation of premature transcription termination products. Premature termination of transcription interferes with the normal transcription and termination of early phase genes of the poxviruses and results in inhibition of replication of the poxviruses. The compositions of the present invention are oligonucleotides comprising a U5NU sequence flanked by ribonucleotides, deoxyribonucleotides or modifications thereof. This invention also provides methods for inhibition of replication of poxvirus including the small poxvirus, Monkeypox virus and vaccinia virus.

A recombinant vaccinia virus derived from the vaccinia virus Ankara (MVA) encoding and capable of expressing the E2 gene of Bovine papillomavirus. Also, the use of the virus in the treatment of lesions caused by papillomavirus.

The present invention relates to an oncolytic virus improved in safety and anticancer effect and a use thereof. The oncolytic virus improved in safety and anticancer effect of the present invention isobtained by inserting an HSV-TK fragment-encoding gene into a TK gene region to delete TK of Vaccinia virus. In addition, the oncolytic virus of the present invention expresses an HSV-TK fragment tophosphorylate GCV so that cancer cells infected with the oncolytic virus and even their neighboring cancer cells can be killed. In addition, GCV is also involved in the suppression of viral proliferation and thus can control side effects caused by a virus even upon the administration of a high dose of the virus. Furthermore, an anticancer effect is increased even though the number of viral particles is reduced due to the suppression of GCV against virus proliferation. Therefore, the oncolytic virus improved in safety and anticancer effect of the present invention can be effectively used for the treatment of cancer.

The present invention discloses recombinant vaccinia virus (VV) virions that are resistant to antiviral defenses and have enhanced anti-tumor activities. In one embodiment, the recombinant VV comprise one or more variant VV proteins that have mutations at one or more neutralizing antibody epitopes, thereby conferring viral escape from the neutralizing antibodies. In another embodiment, the recombinant VV is resistant to complement-mediated neutralization due to the expression of a regulator of complement activation (e.g. CD55). In another embodiment, the recombinant VV has enhanced anti-tumor activities due to the expression of bi-specific antibodies co-targeting cancer cells and immune effector cells, or the expression of a polypeptide blocking the PD-1 pathway. The recombinant vaccinia virus virions can be used to treat cancer in a subject.

The present invention provides a method for treating or ameliorating cerebrovascular diseases in a subject by using peptides isolated from extracts from rabbit skin inflamed by vaccinia virus. The present invention also provides a peptide comprising an amino acid sequence having at least 70% identity to SEQ ID NO: 1, or variants, mutants, derivatives, or fragments thereof.

A process for preparing the modified surface glucoprotein gp160 of human acquired immune deficiency virus 1 in the cowpox virus system, the cowpox virus used to prepare the protein gp160, and the prepared protein gp160 are disclosed. Its advantages are high output and high purity.

Expression vectors ideal for use in vaccinating individuals against disease based on vaccinia virus and other chordopoxviruses having high expression of recombinant genes and low expression of vector genes in target animals, and low expression of recombinant genes and high expression of vector genes in cells used for propagation.

The invention provides a genetically-modified vaccinia virus that is effective for the prevention or treatment of cancer. Specifically, the invention provides: a vaccinia virus containing two polynucleotides which are a polynucleotide that codes for IL-7 and a polynucleotide that codes for IL-12; a combination kit including two vaccinia viruses which are a vaccinia virus containing a polynucleotide that codes for IL-7 and a vaccinia virus containing a polynucleotide that codes for IL-12; and a combination use of the two vaccinia viruses.

The invention relates to the field of vaccines, and discloses a protein vaccinia vaccine and a method for detecting its effectiveness. The protein vaccine contains viral recombinant protein D8L expressed by yeast and with a purity >90% of endotoxin removed. The preparation method is as follows: expressing yeast with a purity >90% 90% of the recombinant protein D8L of vaccinia virus has been treated to remove endotoxin to obtain a recombinant protein D8L solution with an endotoxin content <5 EU / ml. Efficacy testing method is as follows: the recombinant protein D8L solution that removes endotoxin is injected subcutaneously twice to immunize mice. After 21 days, specific antibodies and neutralizing antibodies can be detected in the mouse serum, indicating that the mice have acquired anti-vaccinia virus immunity. immune protection. The protein vaccine of the present invention does not require additional vaccine adjuvants, and can theoretically replace traditional live vaccinia virus vaccines, and play a role in resisting pox virus infections such as smallpox virus.

Expression vectors ideal for use in vaccinating individuals against disease based on vaccinia virus and other chordopoxviruses having high expression of recombinant genes and low expression of vector genes in target animals, and low expression of recombinant genes and high expression of vector genes in cells used for propagation.

The invention relates in various aspects to a synthetic chimeric vaccinia virus or compositions comprising such viruses, and the development and use of systems and methods for producing such synthetic chimeric vaccinia viruses. The synthetic chimeric vaccinia viruses are well suited, among others, as virus vaccines or to generate an oncolytic response and pharmaceutical formulations.

The present invention relates to the therapeutic use of extract from rabbit skin inflamed by vaccinia virus. More specifically, the present invention relates to the use of the extract for preventing or treating cancer, or the use of the extract for stimulating secretion of cytokine by somatic cells in a patient. In addition, the present invention also relates to a drug combination comprising the extract as the first anticancer agent and a second anticancer agent as well as its use for preventing or treating cancer.

The invention relates to a vaccinia virus capping enzyme mutant, a recombinant vector, a recombinant engineering bacterium and application of the vaccinia virus capping enzyme mutant. The vaccinia virus capping enzyme mutant comprises: (a) a polypeptide formed by deleting, replacing or adding one or more amino acids to an amino acid sequence as shown in SEQ ID No.2; or (b) a polypeptide having at least 90% of homology with the polypeptide composed of the amino acid sequence as shown in SEQ ID No.2. The half-life period of the vaccinia virus capping enzyme mutant at 45 DEG C is 35 min or above and is higher than that of a wild type vaccinia virus capping enzyme mutant, and when mRNA is capped at a high temperature, the vaccinia virus capping enzyme mutant still shows excellent catalytic activity and can play an important role in the fields of clinical medicine, influenza vaccines, tumor vaccines, biological pharmacy and the like.